Last Updated : April 22, 2019
Details
FilesGeneric Name:
Blinatumomab
Project Status:
Complete
Therapeutic Area:
Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Manufacturer:
Amgen Canada Inc.
Brand Name:
Blincyto
Project Line:
Reimbursement Review
Project Number:
PC0146-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
38.5 mcg
Tumour Type:
Leukemia
Indications:
Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Funding Request:
Adult patients (i.e., >= 18 years) with Ph+ BCP-ALL, who have relapsed after or are refractory to at least one second-generation or later TKI, or are intolerant to second-generation or later TKIs and intolerant or refractory to imatinib
Sponsor:
Amgen Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : April 22, 2019